Article Figures & Data
Tables
Diagnosis Clinical Indicators Diabetes mellitus Classical clinical course of microalbuminuria, followed by clinical proteinuria, hypertension, and then declining GFR. Hypertension Usually characterized by severely elevated blood pressure readings over a long period, with associated end-organ damage in addition to kidney disease. Nephrotoxic medications Review prescribed and over-the-counter medications as well as intravenous contrast dye or gadolinium exposure. Systemic lupus erythematosus Evaluate for photosensitivity, malar/discoid rashes, oral ulcers, arthritis, serositis, neurological symptoms, hematological findings, ANA/dsDNA positive. HIV nephropathy Signs and symptoms of immunodeficiency; HIV positive on testing. Congestive heart failure Signs and symptoms of heart failure present. Because fluid overload is common in chronic kidney disease, diagnosis is made through echocardiogram to evaluate systolic and diastolic heart function. Genetic syndromes Evaluation of family history is suggestive. Hepatorenal syndrome History or evidence of cirrhosis with resultant portal hypertension, ascites, and renal vasoconstriction. Classically lack significant proteinuria. Nephrolithiasis Evaluate for history of hematuria and symptoms of renal colic. Long-standing obstruction can cause permanent renal impairment. Benign prostatic hypertrophy Evaluate male patients for hesitancy, straining, or weak flow during urination and nocturia. Confirm with prostate exam. Glomerulonephritis Broad category of diseases including postinfectious (streptococcal) as well as various vasculitis diseases. Urinalysis suggestive with presence of red blood cell casts. GFR, glomerular filtration rate; ANA, antinuclear antibodies; dsDNA, double-stranded deoxyribonucleic acid; HIV, human immunodeficiency virus.
Diabetic Medication Renal Dosage* Biguanines Glucophage (metformin) Renal impairment: avoid use Sulfonureas Glucotrol (glipizide) CrCl† <50: decrease dose by 50% Diabeta (glyburide) CrCl† <50: avoid use Amaryl (glimepiride) Renal impairment: start 1 mg daily, increase slowly, monitor glucose Glitazones Actos (pioglitazone) No adjustment Avandia (rosiglitazone) No adjustment Alpha-glucosidase inhibitors Precose (acarbose) Creatinine >2: avoid use Glyset (miglitol) Creatinine >2: avoid use Meglitinides Starlix (nateglinide) No adjustment Prandin (repaglinide) CrCl 20–40: start 0.5 mg before every meal, use titrate with cautionCrCl <20: not defined Incretin mimetics Byetta (exenatide) CrCl 30–80: no adjustmentCrCl <30 & HD: not recommended Januvia (sitagliptin) CrCl 30–49: 50 mg dailyCrCl <30: 25 mg dailyHD/CAPD: no supplement * Dosing recommendations according to Epocrates Essentials (Epocrates Inc., San Mateo, CA).
† Calculated by Cockroft-Gault equation.
CrCl, creatinine clearance (mL/min); HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis.
Stage Complete Blood Count Intact PTH Phosphorus/Calcium Total CO2 3 (GFR 30–59) 12 12 12 12 4 (GFR 15–29) 12 3 3 3 5 (GFR <15) 12 3 1 3 Dialysis 12 3 1 1 Values are presented as monthly intervals.
PTH, parathyroid hormone; GFR, glomerular filtration rate.
- Table 5.
Target Phosphorus and Intact Parathyroid Hormone by Stage of Chronic Kidney Disease
Stage Target Phosphorus (mg/dL) Target Intact PTH (pg/mL) 3 (GFR 30–59) 2.7–4.6 35–70 4 (GFR 15–29) 2.7–4.6 70–110 5 (GFR <15) 3.5–5.5 150–300 PTH, parathyroid hormone; GFR, glomerular filtration rate.